We present two novel fluidic concepts to drastically accelerate the process of mixing in batch-mode (stopped-flow) on centrifugal microfluidic platforms. The core of our simple and robust setup exhibits a microstructured disk with a round mixing chamber rotating on a macroscopic drive unit. In the first approach, magnetic beads which are prefilled into the mixing chamber are periodically deflected by a set of permanent magnets equidistantly aligned at spatially fixed positions in the lab-frame. Their radial positions alternatingly deviate by a slight positive and negative offset from the mean orbit of the chamber to periodically deflect the beads inbound and outbound during rotation. Advection is induced by the relative motion of the beads with respect to the liquid which results from the magnetic and centrifugal forces, as well as inertia. In a second approach--without magnetic beads--the disk is spun upon periodic changes in the sense of rotation. This way, inertia effects induce stirring of the liquids. As a result, both strategies accelerate mixing from about 7 minutes for mere diffusion to less than five seconds. Combining both effects, an ultimate mixing time of less than one second could be achieved.
The hepatitis B virus (HBV), family Hepadnaviridae, is one of most relevant human pathogens. HBV origins are enigmatic, and no zoonotic reservoirs are known. Here, we screened 3,080 specimens from 54 bat species representing 11 bat families for hepadnaviral DNA. Ten specimens (0.3%) from Panama and Gabon yielded unique hepadnaviruses in coancestral relation to HBV. Full genome sequencing allowed classification as three putative orthohepadnavirus species based on genome lengths (3,149-3,377 nt), presence of middle HBV surface and X-protein genes, and sequence distance criteria. Hepatic tropism in bats was shown by quantitative PCR and in situ hybridization. Infected livers showed histopathologic changes compatible with hepatitis. Human hepatocytes transfected with all three bat viruses cross-reacted with sera against the HBV core protein, concordant with the phylogenetic relatedness of these hepadnaviruses and HBV. One virus from Uroderma bilobatum, the tent-making bat, cross-reacted with monoclonal antibodies against the HBV antigenicity determining S domain. Up to 18.4% of bat sera contained antibodies against bat hepadnaviruses. Infectious clones were generated to study all three viruses in detail. Hepatitis D virus particles pseudotyped with surface proteins of U. bilobatum HBV, but neither of the other two viruses could infect primary human and Tupaia belangeri hepatocytes. Hepatocyte infection occurred through the human HBV receptor sodium taurocholate cotransporting polypeptide but could not be neutralized by sera from vaccinated humans. Antihepadnaviral treatment using an approved reverse transcriptase inhibitor blocked replication of all bat hepadnaviruses. Our data suggest that bats may have been ancestral sources of primate hepadnaviruses. The observed zoonotic potential might affect concepts aimed at eradicating HBV.evolution | zoonosis | virome | metagenomics | reverse genetics M ore than 40% of the human population has been infected with the hepatitis B virus (HBV), giving rise to 240 million chronic HBV carriers and ca. 620,000 HBV-associated deaths annually (1). A prophylactic vaccine containing the small HBV genotype A2 surface antigen (SHB) is part of the worldwide Expanded Program on Immunization. Because of the general success of SHBs-based vaccination, global eradication of HBV has been considered achievable (2, 3). Potential for the virus to be eradicated is supported by the fact that there are no known animal reservoirs. However, recent studies addressing the distribution of pathogens related to human viruses in wild animals, including mumps-and measles-related viruses in bats, have uncovered surprising putative novel reservoirs for human-pathogenic viruses (4). SignificanceHepatitis B virus (HBV) is the prototype hepadnavirus; 40% of humans have current or past infection. In a global investigation of viral diversity in bats, we discovered three unique hepadnavirus species. The relatedness of these viruses to HBV suggests that bats might constitute ancestral sources of primate hepadnaviruse...
Myr-preS1 virus binding to NTCP, necessary for productive HBV infection, interferes with the physiological bile acid transport function of NTCP. Therefore, HBV infection via NTCP may be lockable by NTCP substrates and NTCP-inhibiting drugs. This opens a completely new way for an efficient management of HBV infection by the use of NTCP-directed drugs.
A novel design of a piezoelectric silicon micropump is proposed, which provides a constant flow rate over a wide backpressure range of up to 30 kPa. This highly appreciable feature is based on a new serial arrangement of two active valves and relies on both an appropriate electrical actuation sequence of the piezo-actuators and an immanent limitation of the membrane deflection by the valve seats. The design is optimized for the low flow regime ranging from 0.1 to 50 µl min−1. A detailed lumped-parameter model is derived in order to reveal the physics behind this pumping principle and to identify the optimum control scheme. For the fabrication of our device, a comparably simple and robust 2-wafer process is utilized. A thorough experimental investigation demonstrates the high performance of the micropump. The backpressure independence of the flow rate enables high-resolution volumetric dosing within the aforementioned flow range. The stroke volume and hence the resolution of the micropump is adjustable via the upstroke voltage of the actuator between 50 and 200 nl. Depending on this setting typical actuation frequencies range from 0.05 to 5 Hz and the flow rate scales proportional to the frequency within that frequency range.
Shrews, insectivorous small mammals, pertain to an ancient mammalian order. We screened 693 European and African shrews for hepatitis B virus (HBV) homologs to elucidate the enigmatic genealogy of HBV. Shrews host HBVs at low prevalence (2.5%) across a broad geographic and host range. The phylogenetically divergent shrew HBVs comprise separate species termed crowned shrew HBV (CSHBV) and musk shrew HBV (MSHBV), each containing distinct genotypes. Recombination events across host orders, evolutionary reconstructions, and antigenic divergence of shrew HBVs corroborated ancient origins of mammalian HBVs dating back about 80 million years. Resurrected CSHBV replicated in human hepatoma cells, but human-and tupaiaderived primary hepatocytes were resistant to hepatitis D viruses pseudotyped with CSHBV surface proteins. Functional characterization of the shrew sodium taurocholate cotransporting polypeptide (Ntcp), CSHBV/MSHBV surface peptide binding patterns, and infection experiments revealed lack of Ntcp-mediated entry of shrew HBV. Contrastingly, HBV entry was enabled by the shrew Ntcp. Shrew HBVs universally showed mutations in their genomic preCore domains impeding hepatitis B e antigen (HBeAg) production and resembling those observed in HBeAg-negative human HBV. Deep sequencing and in situ hybridization suggest that HBeAg-negative shrew HBVs cause intense hepatotropic monoinfections and low within-host genomic heterogeneity. Geographical clustering and low MSHBV/CSHBVspecific seroprevalence suggest focal transmission and high virulence of shrew HBVs. HBeAg negativity is thus an ancient HBV infection pattern, whereas Ntcp usage for entry is not evolutionarily conserved. Shrew infection models relying on CSHBV/MSHBV revertants and human HBV will allow comparative assessments of HBeAg-mediated HBV pathogenesis, entry, and species barriers.hepatitis B virus | viral evolution | zoonosis | shrew | E antigen T he hepatitis B virus (HBV, genus Orthohepadnavirus) is a ubiquitous pathogen that causes 887,000 deaths annually, predominantly due to cirrhosis and hepatocellular carcinoma after chronic hepatitis B (CHB) (1). Distantly related hepadnaviruses were identified recently in animals other than humans and apes (1). The newly discovered animal viruses revealed that prototypic properties of HBV such as envelopment (2) and presence of an X gene (3) emerged de novo during orthohepadnavirus evolution.Hepadnaviruses are ancient pathogens, likely infecting vertebrates for over 200 million years (3). Placental mammals evolved ∼99 million years ago (mya) and form 2 major clades termed Laurasiatheria and Euarchontoglires (4). The known laurasiatherian HBV hosts belong to several species within the orders Chiroptera (bats) and to one species each within the orders Carnivora (cat) and Artiodactyla (duiker). HBV hosts within the Euarchontoglires include Significance Hepatitis B viruses (HBVs) have existed for millions of years. We describe divergent HBV species in shrews, which are ancient insectivorous mammals. The shrew viruses co...
We present a novel concept of an implantable active microport based on micro technology that incorporates a high-resolution volumetric dosing unit and a drug reservoir into the space of a conventional subcutaneous port. The controlled release of small drug volumes from such an "active microport" is crucial e.g. for innovative methods in cancer treatment or pain therapy. Our microport system delivers a flow rate in the range of 10-1,000 mul/h and enables a patient-specific release profile. The core of our device is a two-stage piezoelectric micropump. It features a backpressure-independent volumetric dosing capability i.e. a stable flow rate is ensured up to a backpressure of 30 kPa. The stroke volume and hence the resolution of the mircopump is voltage controlled and can be preset between 10 and 200 nl. A miniaturized high-performance electronic control unit enables freely programmable dosing profiles. This electronic circuit is optimized for both energy consumption and weight which are both essential for a portable device. The data of an implemented pressure sensor are used to permanently monitor the dosing process and to detect a potential catheter occlusion. A polyurethane soft lithography process is introduced for the fabrication of the prototype. Therewith, a compact multilayer system has been developed which measures only 50 x 35 x 25 mm(3).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.